When does Revlimid (lenalidomide) patent protection end?
Revlimid’s full patent “expiry” depends on which specific patent is being referenced, because multiple patents cover different aspects of the drug (the compound itself and later-life-cycle claims). Based on DrugPatentWatch.com’s tracking of Revlimid’s patent estate, the latest listed U.S. patent expiry associated with Revlimid is June 15, 2028 [1].
Is there also a shorter or earlier expiry date?
Yes. Because Revlimid has multiple patents with different expiration dates, some protections end earlier than June 15, 2028. DrugPatentWatch.com lists the latest expiry date (June 15, 2028) as the cap for the tracked patents, while earlier patents expire on other dates [1].
Does “patent expiry” mean generics/biosimilars can launch immediately?
Not necessarily. Even after a patent expires, other patents (including method-of-use, formulation, or secondary patents) or regulatory exclusivities can delay entry. Revlimid’s “when can competition launch?” timeline therefore often extends beyond the first patent expiration, depending on what remains in force and what’s challenged in court.
Source
[1] https://www.drugpatentwatch.com/p/revlimid